These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26970519)

  • 1. Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.
    Sahota T; Danhof M; Della Pasqua O
    Mutagenesis; 2016 May; 31(3):359-74. PubMed ID: 26970519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development.
    Polak S; Tylutki Z; Holbrook M; Wiśniowska B
    Drug Discov Today; 2019 Jul; 24(7):1344-1354. PubMed ID: 31132414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of concentration-effect relationships in the assessment of QTc interval prolongation.
    France NP; Della Pasqua O
    Br J Clin Pharmacol; 2015 Jan; 79(1):117-31. PubMed ID: 24938719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.
    Taneja A; Della Pasqua O; Danhof M
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1219-1236. PubMed ID: 28894907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of PKPD relationships into benefit-risk analysis.
    Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
    Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
    Sahota T; Sanderson I; Danhof M; Della Pasqua O
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):209-19. PubMed ID: 24667227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
    Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
    J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework to assess the translation of safety pharmacology data to humans.
    Valentin JP; Bialecki R; Ewart L; Hammond T; Leishmann D; Lindgren S; Martinez V; Pollard C; Redfern W; Wallis R
    J Pharmacol Toxicol Methods; 2009; 60(2):152-8. PubMed ID: 19616110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment: the use of clinical utility index.
    Ouellet D
    Expert Opin Drug Saf; 2010 Mar; 9(2):289-300. PubMed ID: 20175698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.